Literature DB >> 28859030

Treatment of Refractory Infantile Hemangiomas and Pulmonary Hypertension With Sirolimus in a Pediatric Patient.

Kelley K Hutchins1, Robert D Ross, Daisuke Kobayashi, Alissa Martin, Madhvi Rajpurkar.   

Abstract

Infantile hemangioma is a benign vascular neoplasm that spontaneously involutes over time. Management, when needed, consists of medications, laser treatment and surgical excision. We describe a 3-year-old girl who presented shortly after birth with diffuse cutaneous hemangiomas, hepatosplenomegaly with liver lesions, anemia, and acute heart failure. She was diagnosed with hepatic and cutaneous infantile hemangioma based on skin biopsy. She developed progressive pulmonary hypertension with numerous pulmonary nodules suspicious for pulmonary arteriovenous malformations. She was started on sirolimus and had significant improvement in her pulmonary hypertension and liver lesions. This report supports prior studies that sirolimus is effective for vascular anomalies including IH refractory to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28859030     DOI: 10.1097/MPH.0000000000000961

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Sirolimus for diffuse intestinal infantile hemangioma with PHACE features: systematic review.

Authors:  Elana P Kleinman; Francine Blei; Denise Adams; Shoshana Greenberger
Journal:  Pediatr Res       Date:  2022-09-30       Impact factor: 3.953

Review 2.  Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?

Authors:  Laura Macca; Domenica Altavilla; Luca Di Bartolomeo; Natasha Irrera; Francesco Borgia; Federica Li Pomi; Federico Vaccaro; Violetta Squadrito; Francesco Squadrito; Mario Vaccaro
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

3.  Infantile hepatic hemangiomas associated with high-output cardiac failure and pulmonary hypertension.

Authors:  Xin-Tong Zhang; Wei-Dong Ren; Guang Song; Yang-Jie Xiao; Fei-Fei Sun; Nan Wang
Journal:  BMC Cardiovasc Disord       Date:  2019-10-11       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.